Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
复制标题
DOI：
10.1093/annonc/mdy218
复制
发表时间：
2018-08-01
影响因子：
50.5
通讯作者：
Taube, J. M.
中科院分区：
文献类型：
--
作者：
Cottrell, T. R.;Thompson, E. D.;Taube, J. M.
背景：新辅助抗pd -1可能改善可切除非小细胞肺癌患者的预后，并为检查与反应相关的病理特征提供了一个关键窗口。对新辅助治疗有主要病理反应的切除，定义为
Background: Neoadjuvant anti-PD-1 may improve outcomes for patients with resectable NSCLC and provides a critical window for examining pathologic features associated with response. Resections showing major pathologic response to neoadjuvant therapy, defined as